MP53-19 PROSTATE CANCER UPGRADING AND UPSTAGING IN A MULTICENTER PROSTATE CANCER REGISTRY

Abstract

You have accessJournal of UrologyProstate Cancer: Staging I1 Apr 2018MP53-19 PROSTATE CANCER UPGRADING AND UPSTAGING IN A MULTICENTER PROSTATE CANCER REGISTRY Maha Husainat, Mohamed Abdelhady, Susan Linsell, Ji Qi, Mazen Abdelhady, and Michigan Urological Surgery Improvement Collaborative Maha HusainatMaha Husainat More articles by this author , Mohamed AbdelhadyMohamed Abdelhady More articles by this author , Susan LinsellSusan Linsell More articles by this author , Ji QiJi Qi More articles by this author , Mazen AbdelhadyMazen Abdelhady More articles by this author , and Michigan Urological Surgery Improvement CollaborativeMichigan Urological Surgery Improvement Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1690AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate the final pathological outcomes and tumor stage of favorable risk prostate cancer (FPCa) treated by radical prostatectomy (RP) in a state wide multicenter registry and to evaluate the factors that would affect the Gleason (GS) upgrade and tumor upstage between prostate biopsy and radical prostatectomy specimens. METHODS Using data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) registry, we identified all patients with FPCa (GS 3+3 or low volume GS 3+4, based on MUSIC Active Surveillance appropriateness criteria) who underwent RP after diagnosis. Primary outcomes of interest include: 1) upgrading on GS from the initial needle biopsy to RP pathology, and 2) pathological T3 or T4 stage. Multivariable logistic regression models were performed to assess the associations between patient characteristics and outcomes. RESULTS A total of 3,159 men were included for analysis. Overall upgrading and upstaging occurred in 40.7% and 14.3% of the patients, respectively. On multivariable analysis, age, BMI, PSA, greatest percentage of involvement in positive cores and Gleason grade 4 in diagnostic biopsy were associated with upgrading on GS (p<0.05). All the aforementioned factors except for BMI were also associated with having pathological T3 or T4 stage (p<0.05). Patients of African American (AA) descent were not at higher risk of tumor upgrade or upstage (p=0.24 for upgrading and p=0.75 for upstaging) compared to White men. CONCLUSIONS Our study found that, baseline tumor characteristics were affecting the final pathologic outcome, while race did not play a role in the final pathologic grade or stage PCa. According to our results we think that AA with FPCa are not at higher risk of tumor upgrade or upstage on surgical intervention. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e711 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Maha Husainat More articles by this author Mohamed Abdelhady More articles by this author Susan Linsell More articles by this author Ji Qi More articles by this author Mazen Abdelhady More articles by this author Michigan Urological Surgery Improvement Collaborative More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...